 On May 8, 2019, the Department of Health and Human Services (HHS) approved a mandate for list prices to be displayed in advertising for any prescription that costs $35 or higher for 30 days of treatment.Ads could also include price comparisons against competitors.PhRMA objected to the rule, arguing that prominent display of list prices would cause confusion because they do not reflect what patients would typically pay under insurance coverage (the rule did require display of a disclaimer stating that those with health insurance may pay a different amount).